Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs EW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 EW Matrix Metrics: RBOT.WS 1 – 9 EW

As of Nov 20, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas EW carries 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. EW 40.0/100 SELL), EW captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (28.8% vs. N/A operating margin) and revenue trajectory (+10.5% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs EW
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.85
-1.95% 1D
Market Cap $59.7B
TTM Revenue $6.67B
Forward P/E 30.1x
Beta / 30D Vol 0.43β · 27% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 24.0 Fund 43.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.7% over 20 days), RSI 59
RSI-14: 59.1 · SMA20: $100.07 · SMA50: $92.22

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 EW)

Columns: Metric · RBOT.WS · EW
1. Valuation Multiples EW
Forward P/E N/M 30.1x
Trailing P/E N/M 60.4x
PEG Ratio N/M 2.32x
EV / Revenue N/M 8.6x
2. Growth & Scale EW
Revenue Growth (YoY) N/A +10.5%
Earnings Growth (YoY) N/A +6.7%
TTM Revenue (USD) N/A $6.67B
Market Cap N/A $59.7B
3. Profitability & Quality EW
Gross Margin N/A 78.0%
Operating Margin N/A 28.8%
Net Profit Margin N/A 15.3%
Return on Equity (ROE) N/A 9.3%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) N/A $1.42B
Cash Flow Margin N/A 21.3%
Net Cash / Leverage N/A ROE $2.41B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EW
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 173.0% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity N/A 49.2% of Rev ($3.28B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs EW (9)
Institutional Metric RBOT.WS EW Criterion Row Edge
Market Capitalization
Scale
N/A $59.7B Larger Scale EW
Trailing P/E Ratio
Valuation
N/M 60.4x Lower Multiple EW
Forward P/E Ratio
Valuation
N/M 30.1x Lower Multiple EW
Revenue Growth (YoY)
Growth
N/A +10.5% Higher Growth EW
Operating Margin (TTM)
Profitability
N/A 28.8% Higher Margin EW
Net Profit Margin
Profitability
N/A 15.3% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
N/A 9.3% Higher ROE EW
52-Week Range Position
Momentum
0% ($0–$0) 82% ($75–$108) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
N/A 0.43β · 27% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 40.0 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $6.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 78.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.32x PEG · 8.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $1.42B ($2.41B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +66.45 pp
RBOT.WS: -67.2% · EW: -0.75%
3M Horizon EW +66.45 pp
RBOT.WS: -67.2% · EW: -0.75%
6M Horizon EW +66.45 pp
RBOT.WS: -67.2% · EW: -0.75%
1Y Horizon EW +66.45 pp
RBOT.WS: -67.2% · EW: -0.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs EW. Trailing 12-month operating profitability (RBOT.WS N/A vs EW 28.8%) and valuation multiples (RBOT.WS N/M vs EW 30.1x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
EW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.67B
Gross Margin78.0%
Op. Margin28.8%
ROE / Fwd P/E9.3% · 30.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 173.0%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $105.43 · IV 28.2%

EW Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($10,543)

Compare $10,543 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 28.2% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $105 / $110 Bull Call Spread

Buy 1x $105C · Sell 1x $110C · 30d

Net Entry $185 Debit
T+5d @ +5% Move +$124 (+67%)
Max Risk / Buffer $185 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $100 / $95 Bull Put Spread

Sell 1x $100P · Buy 1x $95P · 30d

Net Entry $64 Credit
Max Credit / Yield +$64 (+14.7% RoM)
Max Risk / Buffer -5.8% Cushion ($436 Mgn)
5d Edge & Liquidity 77% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $105 / $100 Bear Put Spread

Buy 1x $105P · Sell 1x $100P · 30d

Net Entry $130 Debit
T+5d @ -5% Drop +$136 (+104%)
Max Risk / Buffer $130 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $59.7B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs EW Key Questions & Quantitative Answers

As of Nov 20, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas EW carries 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. EW 40.0/100 SELL), EW captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (28.8% vs. N/A operating margin) and revenue trajectory (+10.5% vs. N/A YoY).

EW leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $6.67B for EW. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.

EW screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EW trades at 30.1x Forward P/E, 60.4x Trailing P/E, 2.32x PEG, and 8.6x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus EW (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, EW carries 173.0% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.43β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.